Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G | 2024-02-14 | BAKER BROS. ADVISORS LP | Athira Pharma, Inc. | 3,153,807 | 8.3% | EDGAR |
SC 13D/A | 2023-12-29 | PERCEPTIVE ADVISORS LLC | Athira Pharma, Inc. | 5,402,964 | 14.2% | EDGAR |
SC 13G/A | 2023-07-07 | BlackRock Inc. | Athira Pharma, Inc. | 669,768 | 1.8% | EDGAR |
SC 13G | 2023-04-20 | KAYNE RICHARD A | Athira Pharma, Inc. | 1,983,668 | 5.3% | EDGAR |
SC 13G/A | 2023-02-14 | RTW INVESTMENTS, LP | Athira Pharma, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2023-02-01 | BlackRock Inc. | Athira Pharma, Inc. | 2,363,221 | 6.2% | EDGAR |
SC 13G/A | 2023-01-30 | FRANKLIN RESOURCES INC | Athira Pharma, Inc. | 0 | 0.0% | EDGAR |
SC 13D/A | 2022-07-01 | PERCEPTIVE ADVISORS LLC | Athira Pharma, Inc. | 4,811,149 | 12.8% | EDGAR |
SC 13G/A | 2022-02-14 | RTW INVESTMENTS, LP | Athira Pharma, Inc. | 1,906,557 | 5.1% | EDGAR |
SC 13G/A | 2022-02-14 | Venrock Healthcare Capital Partners II, L.P. | Athira Pharma, Inc. | 1,000,000 | 2.7% | EDGAR |
SC 13G/A | 2022-02-14 | VIKING GLOBAL INVESTORS LP | Athira Pharma, Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2022-02-04 | BlackRock Inc. | Athira Pharma, Inc. | 2,455,684 | 6.6% | EDGAR |
SC 13G | 2022-02-03 | FRANKLIN RESOURCES INC | Athira Pharma, Inc. | 2,080,050 | 5.6% | EDGAR |
SC 13G/A | 2021-02-16 | Venrock Healthcare Capital Partners II, L.P. | Athira Pharma, Inc. | 1,691,623 | 5.2% | EDGAR |
SC 13G/A | 2021-02-16 | VIKING GLOBAL INVESTORS LP | Athira Pharma, Inc. | 2,120,653 | 6.0% | EDGAR |
SC 13G | 2021-02-16 | KAWAS LEEN | Athira Pharma, Inc. | 1,693,102 | 5.2% | EDGAR |
SC 13G/A | 2021-02-12 | RTW INVESTMENTS, LP | Athira Pharma, Inc. | 2,685,779 | 8.3% | EDGAR |
SC 13D | 2021-02-08 | PERCEPTIVE ADVISORS LLC | Athira Pharma, Inc. | 3,425,916 | 9.8% | EDGAR |
SC 13G | 2020-11-16 | Venrock Healthcare Capital Partners II, L.P. | Athira Pharma, Inc. | 1,657,623 | 5.1% | EDGAR |
SC 13G | 2020-09-28 | VIKING GLOBAL INVESTORS LP | Athira Pharma, Inc. | 2,120,653 | 6.9% | EDGAR |